HomeCompareSZUKF vs BTI

SZUKF vs BTI: Dividend Comparison 2026

SZUKF yields 1.93% · BTI yields 5.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BTI wins by $6.5K in total portfolio value
10 years
SZUKF
SZUKF
● Live price
1.93%
Share price
$30.30
Annual div
$0.59
5Y div CAGR
24%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$31.2K
Annual income
$2,432.69
Full SZUKF calculator →
BTI
BTI
● Live price
5.38%
Share price
$58.47
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.7K
Annual income
$2,786.64
Full BTI calculator →

Portfolio growth — SZUKF vs BTI

📍 BTI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSZUKFBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SZUKF + BTI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SZUKF pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SZUKF
Annual income on $10K today (after 15% tax)
$164.32/yr
After 10yr DRIP, annual income (after tax)
$2,067.79/yr
BTI
Annual income on $10K today (after 15% tax)
$457.40/yr
After 10yr DRIP, annual income (after tax)
$2,368.64/yr
At 15% tax rate, BTI beats the other by $300.86/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SZUKF + BTI for your $10,000?

SZUKF: 50%BTI: 50%
100% BTI50/50100% SZUKF
Portfolio after 10yr
$34.5K
Annual income
$2,609.67/yr
Blended yield
7.57%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

SZUKF
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
2.7
Piotroski
4/9
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.6% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SZUKF buys
0
BTI buys
0
No recent congressional trades found for SZUKF or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSZUKFBTI
Forward yield1.93%5.38%
Annual dividend / share$0.59$3.15
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR24%11.3%
Portfolio after 10y$31.2K$37.7K
Annual income after 10y$2,432.69$2,786.64
Total dividends collected$9.6K$14.3K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy

Year-by-year: SZUKF vs BTI ($10,000, DRIP)

YearSZUKF PortfolioSZUKF Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$10,940$239.72$11,299$598.92$359.00BTI
2$12,009$303.91$12,794$703.91$785.00BTI
3$13,237$386.64$14,518$829.07$1.3KBTI
4$14,657$493.86$16,513$978.64$1.9KBTI
5$16,317$633.73$18,827$1,157.84$2.5KBTI
6$18,277$817.58$21,518$1,373.12$3.2KBTI
7$20,617$1,061.28$24,657$1,632.46$4.0KBTI
8$23,448$1,387.40$28,329$1,945.74$4.9KBTI
9$26,918$1,828.58$32,637$2,325.33$5.7KBTI
10$31,235$2,432.69$37,708$2,786.64$6.5KBTI

SZUKF vs BTI: Complete Analysis 2026

SZUKFStock

Suzuken Co., Ltd., together with its subsidiaries, primarily engages in the wholesale of pharmaceuticals in Japan and internationally. The company operates in four segments: Pharmaceutical Distribution Business, Pharmaceutical Manufacturing Business, Pharmacy Business, and Healthcare-Related Services Business. The Pharmaceutical Distribution Business segment procures ethical drugs, diagnostic reagents, medical equipment and supplies, and other health-related items from manufacturers and supplies to medical institutions and pharmacies. The Pharmaceutical Manufacturing Business segment engages in the research and development, manufacturing, and marketing of ethical pharmaceuticals and diagnostic products focusing on the areas of diabetes and kidney diseases. The Pharmacy Business segment provides services through family pharmacists, as well as improves the operations of local pharmacies and provides educational support. The Healthcare-Related Services Business segment provides manufacturer support services, such as contract distribution for manufacturers; distribution of orphan drugs; and nursing care services, as well as develops, manufactures, and sells electrocardiographs, sphygmomanometers, stethoscopes, medical materials, and health promotion equipment. Suzuken Co., Ltd. also publishes medical magazines for medical institutions. The company has collaboration with Bushu Pharmaceuticals Ltd. provide contract specialty drug services. Suzuken Co., Ltd. was founded in 1932 and is headquartered in Nagoya, Japan.

Full SZUKF Calculator →

BTIConsumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this SZUKF vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SZUKF vs SCHDSZUKF vs JEPISZUKF vs OSZUKF vs KOSZUKF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.